TaiGen
Overview
Milestones
Business Model
Steering Committee
Board of Directors
Management
Pipeline
Clinical Pipeline
Preclinical Pipeline
Product Overview
Nemonoxacin
Burixafor
TG-2349
Development Projects
Nemonoxacin
Burixafor
TG-2349
Research
Anti-influenza Drug And Anti-Gram Negative Bacteria Drug
News
Stakeholders Section
Presentation
Corporate brief introduction
Institutional investors conference on Jul. 06, 2016
CLSA China Healthcare-Drug Innovation Forum on Jan. 20-21,2016
Morgan Stanley Fourteenth Annual Asia Pacific Summit on Nov. 17-18,2015
CIMB Pan-Asia Healthcare Conference on Oct. 8-9, 2015
Shareholders services
IPO Conference
Corporate governance
Contacts
Location
Join Us
Home
中文
- TaiGen’s Taigexyn (Nemonoxacin) Will Be Launched in Mainland China in ...
(9/21/2016 )
- TaiGen Biotechnology Out-Licensed Taigexyn (Nemonoxacin) to Productos ...
(8/25/2016 )
- TaiGen Biotechnology Announces Furaprevir (TG-2349) Received Clinical ...
(8/19/2016 )
- TaiGen Biotechnology Receives Market Approval from the China Food and ...
(6/13/2016 )
- TaiGen Presented Clinical Data of Furaprevir (TG-2349) at the Internat...
(4/18/2016 )
Nemonoxacin
Broad-spectrum Antibiotic
Burixafor
Novel Stem Cell Mobilizer
TG-2349
Hepatitis C Virus Protease Inhibitor
